We are live on ! Find out more
SWTX

SpringWorks Therapeutics

Delisted

SWTX was delisted on the 30th of June, 2025.

306 hedge funds and large institutions have $3.29B invested in SpringWorks Therapeutics in 2025 Q1 according to their latest regulatory filings, with 113 funds opening new positions, 85 increasing their positions, 86 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

414% more first-time investments, than exits

New positions opened: 113 | Existing positions closed: 22

141% more call options, than puts

Call options by funds: $287M | Put options by funds: $119M

42% more funds holding

Funds holding: 216306 (+90)

29% more funds holding in top 10

Funds holding in top 10: 79 (+2)

13% more capital invested

Capital invested by funds: $2.92B → $3.29B (+$368M)

1% less repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 86

9.3% less ownership

Funds ownership: 108.76%99.46% (-9.3%)

Holders
306
Holders Change
+90
Holders Change %
+41.67%
% of All Funds
4.1%
Holding in Top 10
9
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+28.57%
% of All Funds
0.12%
New
113
Increased
85
Reduced
86
Closed
22
Calls
$287M
Puts
$119M
Net Calls
+$168M
Net Calls Change
+$170M
Name Holding Trade Value Shares
Change
Change in
Stake
PIP
76
Palisades Investment Partners
California
$6.02M +$93.6K +2,033 +2%
PFM
77
Privium Fund Management
Netherlands
$5.47M +$5.71M +123,980 New
UBS AM
78
UBS AM
Illinois
$5.35M +$97.8K +2,125 +2%
TS
79
Twin Securities
New York
$5.29M +$5.52M +119,828 New
FCM
80
Farallon Capital Management
California
$5.21M +$5.43M +118,000 New
CM
81
Caption Management
Oklahoma
$5.16M +$5.39M +116,994 New
Swiss National Bank
82
Swiss National Bank
Switzerland
$5.09M -$69K -1,500 -1%
TD Asset Management
83
TD Asset Management
Ontario, Canada
$5.05M -$415K -9,006 -7%
Envestnet Asset Management
84
Envestnet Asset Management
Illinois
$5.04M -$345K -7,489 -6%
Rafferty Asset Management
85
Rafferty Asset Management
New York
$4.9M -$553K -12,017 -10%
RhumbLine Advisers
86
RhumbLine Advisers
Massachusetts
$4.65M +$162K +3,517 +3%
Manulife (Manufacturers Life Insurance)
87
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4.64M -$13.9M -302,466 -74%
AllianceBernstein
88
AllianceBernstein
Tennessee
$4.28M +$951K +20,656 +27%
CS
89
Candriam SCA
Luxembourg
$4.27M -$3.1M -67,237 -41%
OCM
90
Ovata Capital Management
Hong Kong
$4.22M +$4.4M +95,664 New
Royal Bank of Canada
91
Royal Bank of Canada
Ontario, Canada
$4.11M +$1.56M +33,869 +57%
RA
92
RFG Advisory
Alabama
$3.93M +$4.1M +88,995 New
BGIM
93
Boussard & Gavaudan Investment Management
United Kingdom
$3.87M +$3.98M +86,500 New
SC
94
Shay Capital
New York
$3.8M +$3.97M +86,200 New
KC
95
Kryger Capital
United Kingdom
$3.6M +$3.76M +81,663 New
Assenagon Asset Management
96
Assenagon Asset Management
Luxembourg
$3.51M +$3.67M +79,640 New
TCM
97
Tang Capital Management
California
$3.28M
EI
98
EAM Investors
California
$3.17M +$3.31M +71,941 New
Toronto Dominion Bank
99
Toronto Dominion Bank
Ontario, Canada
$3.09M +$3.22M +70,010 New
HS
100
HighVista Strategies
Massachusetts
$3.03M

SWTX Hedge Fund Activity: Q1 2025 in Review

306 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q1 2025, worth a combined $3.29B — up 13% from $2.92B a quarter earlier.

Buyers outnumbered sellers: 113 funds opened new SWTX positions and 22 closed out — a net gain of 91 holders — while 85 added to existing stakes and 86 trimmed.

The largest buyer was D.E. Shaw & Co, adding an estimated $58.7M. The largest seller was Deep Track Capital, exiting entirely with an estimated $125M sold.

  • 306 institutional investors held SpringWorks Therapeutics (SWTX) as of Q1 2025, up from 216 in Q4 2024.
  • Funds reported $3.29B of SpringWorks Therapeutics stock for Q1 2025, up 13% quarter-over-quarter.
  • 113 funds opened new SpringWorks Therapeutics positions in Q1 2025 and 22 closed out, a net change of +91 holders.
  • The largest SpringWorks Therapeutics buyer in Q1 2025 was D.E. Shaw & Co, an estimated $58.7M added.
  • The largest SpringWorks Therapeutics seller in Q1 2025 was Deep Track Capital, an estimated $125M sold.

Based on aggregated 13F filings for Q1 2025.